3-((2S,3R)-2-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoic Acid
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

204589-82-23-((2S,3R)-2-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoic Acid

● In Stock

Catalogue No.:VE009520
CAS No.:204589-82-2
Mol. Formula:C25H22FNO4
Mol. Weight:419.44 g/mol

Additional information on CAS 204589-82-2

Parent drug

Candesartan

IUPAC Name

3-((2S, 3R)-2-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoic Acid

Synonyms

N/A

Description

3-((2S,3R)-2-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidine-3-yl)propanoic Acid (CAS No: 204589-82-2) Or 3-((2S,3R)-2-(4-(Benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidine-3-yl)propanoic Acid, It is an impurity present in Candesartan, candesartan is a long-acting agent, is an act by blocking the activation of angiotensin I receptors, It has antihypertensive agents or other agents that block the RAAS for the control of hypertension and reduction of key CV risk factors such as microalbuminuria, heart failure, retinopathy, and carotid intima medial thickness.

References

Okpechi. (2010). Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integrated Blood Pressure Control, 45. https://doi.org/10.2147/ibpc.s9963

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url